What baseline and follow‑up urinalysis should be performed for a patient initiating lithium therapy?

Baseline and Follow-Up Urinalysis for Lithium Therapy

Before initiating lithium therapy, obtain a baseline urinalysis, and then monitor urinalysis every 6 months during ongoing treatment, along with serum creatinine, BUN, and electrolytes. 1, 2

Baseline Testing (Before Starting Lithium)

Prior to lithium initiation, the following baseline assessments are essential:

• Urinalysis (to detect pre-existing proteinuria, hematuria, or other abnormalities)
• Serum creatinine and BUN (to establish baseline renal function)
• Electrolytes (sodium, potassium)
• Thyroid function tests
• Complete blood count
• Serum calcium
• Pregnancy test (in females of childbearing age) 3

The baseline urinalysis serves to identify any pre-existing kidney disease that would contraindicate lithium use or require closer monitoring 4.

Follow-Up Monitoring Schedule

The KDIGO guidelines provide the strongest recommendation (1A level) that all patients taking potentially nephrotoxic agents such as lithium should have their GFR, electrolytes, and drug levels regularly monitored. 1, 2

Routine Monitoring Every 6 Months:

• Urinalysis
• Serum creatinine and calculated GFR/eGFR
• Electrolytes (sodium, potassium)
• Lithium levels (though these should be checked every 3 months during maintenance therapy)
• Thyroid function tests 1, 3

More Frequent Monitoring Required When:

• Dose changes occur - check within 2-4 weeks
• Patient becomes acutely unwell - immediate assessment
• Signs of lithium toxicity appear - immediate assessment
• Declining urine concentrating ability - may warrant every 2-3 months 1

What to Look for in Urinalysis

The urinalysis should specifically assess for:

1. Urine specific gravity/osmolality - Low values (<1.010) suggest impaired concentrating ability, an early sign of lithium-induced nephrogenic diabetes insipidus 5, 6

2. Proteinuria - Can indicate lithium-induced tubular dysfunction or glomerular damage. Research shows proteinuria can be detected even when eGFR remains >90 mL/min/1.73 m² 7

3. Microscopic hematuria - May indicate structural kidney damage

4. Pyuria - Could suggest interstitial nephritis

5. Glycosuria - In absence of diabetes, may indicate tubular dysfunction

Clinical Context and Pitfalls

Critical caveat: Lithium is nephrotoxic and may cause renal tubular dysfunction with prolonged use even at therapeutic levels 1. The evidence shows that:

• 51% of lithium-treated patients develop impaired renal concentrating ability 6
• Detrimental effects on renal function are typically detected after ≥8 years of use 7
• Duration of lithium therapy is inversely associated with both renal concentrating ability and eGFR 7, 6

Important Practice Points:

Maintain hydration during intercurrent illness and temporarily discontinue lithium in patients with GFR <60 mL/min/1.73 m² who develop serious illness that increases AKI risk 1, 2.

Avoid concomitant NSAIDs, as they increase lithium toxicity risk and nephrotoxicity 1.

Clinical symptoms (polyuria, polydipsia) do not reliably predict impaired renal concentrating ability - objective testing is essential 6.

The spot urine protein/creatinine ratio is a cost-effective and practical alternative to 24-hour urine collections for monitoring proteinuria in lithium-treated patients 7.

Risk-Benefit Consideration:

While lithium monitoring requires vigilance, the drug remains highly effective for mood stabilization in bipolar disorder. The risk-benefit of lithium in each specific clinical situation must be carefully weighed 1, particularly in patients with pre-existing renal impairment (GFR <60 mL/min/1.73 m²), where lithium may still be used with extreme caution, daily monitoring, and dose adjustment 4.